PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 29406904-7 2018 Compared with the AZA group, the MMF group and the RTX group decreased the AQP-4-IgG titre evidently and caused fewer adverse events. Azathioprine 18-21 aquaporin 4 Homo sapiens 75-80 24647557-4 2014 RESULTS: This is the largest reported cohort of AQP4-Ab positive patients treated with AZA. Azathioprine 87-90 aquaporin 4 Homo sapiens 48-52 17178220-1 2007 Carbonic anhydrase inhibitors AZA, EZA, and 4-acetamidobenzsulfonamide were found to inhibit human AQP4-M23 mediated water transport by 80%, 68%, and 23%, respectively, at 20 microM in an in vitro functional assay. Azathioprine 30-33 aquaporin 4 Homo sapiens 99-103 17178220-2 2007 AZA was found to have an IC50 against AQP4 of 0.9 microM. Azathioprine 0-3 aquaporin 4 Homo sapiens 38-42 34797551-8 2022 Meanwhile, the ARR also decreased in all AQP4-Ab groups (from 0.3 to 0.2 in RTX, from 0.9 to 0.5 in AZA, and from 0.9 to 0.4 in MMF). Azathioprine 100-103 aquaporin 4 Homo sapiens 41-45 34797551-14 2022 CONCLUSIONS: RTX, AZA, and MMF therapies efficiently lowered the relapse frequency and disability in both of the AQP4-Ab seropositive or seronegative patients with NMO. Azathioprine 18-21 aquaporin 4 Homo sapiens 113-117 27623738-4 2016 AZA is an antiepileptic drug that has been shown to inhibit AQP4 expression and in this study we investigate the drug as a therapeutic to mitigate the extent of mTBI induced cellular edema. Azathioprine 0-3 aquaporin 4 Homo sapiens 60-64